What happened with ACRS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Aclaris Therapeutics is a clinical-stage biotechnology company developing treatments for immuno-inflammatory diseases. Its candidates include the biologic drugs bosakitug and ATI-052 and the oral drug ATI-2138. It licensed bosakitug and ATI-052 from Biosion, with exclusive development and commercialization rights outside Greater China; those rights carry milestone and royalty payment obligations to Biosion.
Most revenue comes from licensing intellectual property to other companies, through upfront payments, payments when contractual milestones are reached, and royalties. Existing agreements include a license with Sun Pharma. Laboratory services provide a smaller revenue stream. Aclaris has no approved products generating revenue, so it is not an established seller of its own medicines.
Aclaris seeks partners to advance candidates through development, marketing approval and commercialization. Future income from these programs depends on securing partnerships and on partners obtaining approvals and selling the resulting medicines. It also relies on outside manufacturers for clinical-trial supplies. Recent funding has come primarily from share sales and non-dilutive financing, and further development requires additional capital.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Aclaris's prospects hinge on clinical results and development partners for its immuno-inflammatory pipeline, including bosakitug and ATI-052 licensed from Biosion.
Corvus Pharmaceuticals' oral soquelitinib competes with Aclaris's ATI-2138 in atopic dermatitis; both are developing medicines that block ITK, a protein involved in immune-cell activity. Watch Corvus's atopic dermatitis trial results for the competition ATI-2138 could face if approved.
Kymera Therapeutics' oral STAT6 program competes with Aclaris's oral ATI-2138 and biologic candidates as treatments that act throughout the body for atopic dermatitis. Its KT-621 development results are the relevant watchpoint, rather than Kymera's other research programs.
Nektar Therapeutics' rezpegaldesleukin competes with Aclaris's bosakitug and ATI-2138 as a whole-body treatment for atopic dermatitis, but works through a different immune mechanism. Its development results offer a comparison with a different approach, not a direct test of Aclaris's drugs.
Upstream Bio's verekitug trials inform the pathway Aclaris targets with bosakitug: verekitug blocks the receptor that receives TSLP signals, while bosakitug blocks TSLP itself. Watch its severe asthma and nasal-polyp trial results, while keeping in mind that Aclaris's clinical focus remains skin diseases and respiratory development outside Greater China depends on partners.
Sanofi's marketed dupilumab and investigational lunsekimig compete with Aclaris's biologic candidates that target inflammatory signals in atopic dermatitis and potentially asthma. Lunsekimig's development is the watchpoint for emerging competition, alongside the existing dupilumab treatment.
Regeneron's dupilumab competes for the atopic dermatitis patients Aclaris hopes to treat with bosakitug and ATI-052. It provides an efficacy benchmark for developing those candidates, making dupilumab's treatment results more relevant than Regeneron's eye-drug sales.
Pfizer competes directly with Aclaris's ATI-052 by developing antibodies intended to block both TSLP and IL-4Rα, and already sells atopic dermatitis treatments competing with Aclaris's broader pipeline. Watch development of PF-07275315 for the closest overlap with ATI-052.
ImageneBio's IMG-007 competes with Aclaris's biologic and oral programs as a whole-body treatment for atopic dermatitis. The antibody blocks signaling through OX40 on activated immune cells without depleting them; its trials are exploring whether its long half-life can allow less frequent dosing.
Generate Biomedicines' investigational antibody GB-0895 competes with Aclaris's bosakitug by targeting the TSLP pathway. GB-0895's clinical progress is the relevant news for this rivalry; Generate had no candidate approved for sale as of its prospectus.
Incyte's topical ruxolitinib competes with Aclaris's dermatology pipeline for atopic dermatitis treatment. Its OPZELURA cream business is the relevant part to watch, rather than its separate hematology and oncology medicines.
AbbVie's upadacitinib competes with Aclaris's biologic candidates in atopic dermatitis and could compete with oral ATI-2138 if it is approved. Upadacitinib's immuno-inflammatory treatment results are the relevant comparison, not AbbVie's company-wide performance.
Eli Lilly's lebrikizumab and baricitinib compete with Aclaris's immuno-inflammatory candidates, but the Lilly license no longer gives Aclaris a financial interest. Aclaris sold its remaining interest in July 2024, so Lilly's OLUMIANT sales for alopecia areata no longer provide that royalty exposure.
Incyte Genomics Inc earningsINCY
Incyte’s report will show how its OPZELURA cream is faring in atopic dermatitis, a market Aclaris hopes to enter with its own candidates.
Look for Incyte’s discussion of OPZELURA and its performance. Strong results would show that a topical treatment can attract atopic dermatitis patients, leaving Aclaris’s skin-disease candidates with a formidable competitor; weak results would point to a tougher market for this approach, but would not establish whether Aclaris’s candidates work.
Regeneron Pharmaceuticals Inc earningsREGN
Regeneron’s report will show how its dupilumab treatment is faring with atopic dermatitis patients whom Aclaris hopes to treat with its own candidates.
Look for Regeneron’s account of dupilumab’s treatment performance. Strong results would show that Aclaris’s candidates face competition from an established therapy; weaker results could leave room for alternatives, but would not show that Aclaris’s drugs work.
Corvus Pharmaceuticals, Inc. earningsCRVS
Corvus Pharmaceuticals’ report will show how its oral ITK-targeting drug is progressing in atopic dermatitis, where it directly overlaps with Aclaris’s ATI-2138.
Look for progress in Corvus’s atopic dermatitis trials of oral soquelitinib. Convincing efficacy or development progress would show another oral drug blocking the same protein is pursuing the same patients; setbacks could ease this direct competitive pressure, but Aclaris’s own trials still have to establish ATI-2138’s potential.
Pfizer Inc. earningsPFE
Pfizer’s report will show how its PF-07275315 antibody, designed to block both TSLP and IL-4Rα, is progressing against the approach Aclaris is pursuing with ATI-052.
Look for Pfizer’s update on PF-07275315’s development. Strong progress would mean Aclaris’s ATI-052 faces a program with substantial overlap in its targets; weak progress would lessen that particular competitive pressure, but would not establish whether ATI-052 works.
Aclaris Therapeutics, Inc. earningsThis company
Aclaris Therapeutics’ report will show whether licensing and laboratory-service revenue is helping fund the research and development of its drug candidates.
Read licensing revenue and laboratory-service revenue alongside research and development spending. Rising licensing receipts with contained development costs would show partner income helping fund the pipeline; falling licensing receipts as spending rises would mean development depends more on existing cash or new partnerships and financing.
Generate Biomedicines, Inc. earningsGENB
Generate Biomedicines’ report will show how its TSLP-pathway antibody GB-0895 is progressing alongside Aclaris’s own TSLP-blocking candidate, bosakitug.
Look for clinical progress with GB-0895. Strong progress would show another antibody targeting the TSLP pathway is advancing, putting bosakitug in direct competition on that pathway; setbacks could ease that pressure, but would not establish that bosakitug works.
